STOCK TITAN

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:40 p.m. ET. The company will also conduct investor meetings during the conference. A live webcast of the chat will be accessible on their website, with a replay available for 30 days. eFFECTOR focuses on developing selective translation regulator inhibitors (STRIs) for cancer treatment, with its lead candidate, tomivosertib, currently in a Phase 2b trial for metastatic non-small cell lung cancer.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference.

A live webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

Contacts:

Investors:
Stephanie Carrington
Westwicke, an ICR Company
646-277-1282
Stephanie.Carrington@westwicke.com

Media:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi.chokeir@canalecomm.com


FAQ

What is the date and time for eFFECTOR's fireside chat at the 2021 Cantor Virtual Global Healthcare Conference?

eFFECTOR's fireside chat is scheduled for September 28, 2021, at 2:40 p.m. ET.

Where can I watch the live webcast of eFFECTOR's fireside chat?

The live webcast will be available on the 'Events and Presentation' page of eFFECTOR's website.

What is the focus of eFFECTOR Therapeutics?

eFFECTOR Therapeutics focuses on developing selective translation regulator inhibitors (STRIs) for the treatment of cancer.

What is the lead product candidate of eFFECTOR and what trial is it involved in?

The lead product candidate is tomivosertib, which is currently being evaluated in the KICKSTART Phase 2b trial for metastatic non-small cell lung cancer.

Is eFFECTOR involved in any COVID-19 related research?

Yes, eFFECTOR is evaluating zotatifin as a potential host-directed anti-viral therapy for mild to moderate COVID-19 under a grant from the Defense Advanced Research Projects Agency.

EFFECTOR THERAPUTCS INC

OTC:EFTR

EFTR Rankings

EFTR Latest News

EFTR Stock Data

611.57k
4.57M
2.91%
6.31%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH